Immunotech Biopharm Ltd (6978.HK)
HKD 3.92
(-0.25%)
HKD 3.92
(-0.25%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -178.83 Million CNY | 24.28% |
| 2022 | -236.16 Million CNY | 24.39% |
| 2021 | -324.33 Million CNY | 23.08% |
| 2020 | -333.98 Million CNY | -309.33% |
| 2019 | -86.78 Million CNY | -232.07% |
| 2018 | -42.32 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -42.34 Thousand CNY | 19.73% |
| 2024 Q2 | -42.34 Thousand CNY | 0.0% |
| 2023 Q1 | -36.66 Thousand CNY | 31.58% |
| 2023 Q2 | -36.66 Thousand CNY | 0.0% |
| 2023 Q3 | -52.75 Thousand CNY | -43.89% |
| 2023 FY | - CNY | 24.28% |
| 2023 Q4 | -52.75 Thousand CNY | 0.0% |
| 2022 Q2 | -61.96 Thousand CNY | 0.0% |
| 2022 Q4 | -53.58 Thousand CNY | 0.0% |
| 2022 Q3 | -53.58 Thousand CNY | 13.53% |
| 2022 Q1 | -61.96 Thousand CNY | 32.65% |
| 2022 FY | - CNY | 24.39% |
| 2021 Q2 | -70.16 Thousand CNY | 0.0% |
| 2021 FY | - CNY | 23.08% |
| 2021 Q4 | -92 Thousand CNY | 0.0% |
| 2021 Q3 | -92 Thousand CNY | -31.14% |
| 2021 Q1 | -70.16 Thousand CNY | 35.77% |
| 2020 FY | - CNY | -309.33% |
| 2020 Q4 | -109.23 Thousand CNY | 0.64% |
| 2020 Q3 | -109.93 Thousand CNY | -89.07% |
| 2020 Q2 | -58.14 Thousand CNY | 0.0% |
| 2020 Q1 | -58.14 Thousand CNY | -138.27% |
| 2019 Q2 | -21.23 Thousand CNY | 0.0% |
| 2019 Q1 | -21.23 Thousand CNY | 0.0% |
| 2019 Q4 | -24.4 Thousand CNY | 8.41% |
| 2019 FY | - CNY | -232.07% |
| 2019 Q3 | -26.64 Thousand CNY | -25.49% |
| 2018 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 91.23 Million HKD | 296.012% |
| CK Life Sciences Int'l., (Holdings) Inc. | 486.79 Million HKD | 136.736% |